The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 05, 2016

Filed:

Mar. 07, 2012
Applicants:

Paula J. Bates, Louisville, KY (US);

Mohammad Tariq Malik, Prospect, KY (US);

Francesca R. Salipur, Louisville, KY (US);

Inventors:

Paula J. Bates, Louisville, KY (US);

Mohammad Tariq Malik, Prospect, KY (US);

Francesca R. Salipur, Louisville, KY (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/215 (2006.01); A61K 31/22 (2006.01); G01N 33/574 (2006.01); C12Q 1/68 (2006.01); A61K 31/045 (2006.01); C07K 16/18 (2006.01); G01N 33/53 (2006.01);
U.S. Cl.
CPC ...
G01N 33/5748 (2013.01); A61K 31/045 (2013.01); C07K 16/18 (2013.01); C12Q 1/6886 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01); G01N 33/53 (2013.01);
Abstract

Provided herein are methods for predicting efficacy of a DNA (cytosine-5)-methyltransferase 1 (DNMT1) inhibitor treatment in a subject having a cancer, methods of identifying a subject having a cancer that is more likely to respond to a DNMT1 inhibitor treatment, and methods of selecting a treatment for a subject having a cancer that include determining a level of SOX9 in a sample containing cells from a subject having a cancer. Also provided are methods of treating a subject having a cancer that include selectively administering a DNMT1 inhibitor to a subject having cancer determined to have an elevated level of SOX9 in a sample containing cells from the subject compared to a reference level. Also provided are antibodies and antigen-binding antibody fragments that specifically bind to SOX9, and nucleic acid sequences that contain at least 10 nucleotides complementary to a contiguous sequence present in a SOX9 nucleic acid for use in these methods.


Find Patent Forward Citations

Loading…